IP Library Granted Patent US 8,119,400
Granted Patent B2
US 8,119,400 · App. 11/890,318 · Granted Feb 21, 2012

Methods of inhibiting smooth muscle cell migration and proliferation

Assignee: Beth Isreal Deaconess Medical Center, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,119,400
App. No.
11/890,318
Granted
Feb 21, 2012
Kind
B2
Abstract

In particular embodiments, the present invention provides methods of inhibiting smooth muscle cell responses and methods of treating or preventing vascular proliferative disease caused by smooth muscle cell migration and proliferation. More specifically, smooth muscle cell responses are inhibited by introducing an agent into smooth muscle cells, wherein the agent inhibits an activity of one or more members of the myristoylated alanine-rich C kinase substrate (MARCKS) family of proteins. The invention also provides methods of inhibiting expression of one or more genes encoding a member of the MARCKS family of proteins in a cell.

Claims (18)

1. A method of inhibiting at least one vascular smooth muscle cell response selected from the group consisting of cell proliferation and cell migration, the method comprising transfecting vascular smooth muscle cells with a nucleic acid molecule that comprises a nucleotide sequence that is at least 90% homologous to a portion of SEQ ID NO: 3, wherein said nucleic acid molecule hybridizes to SEQ ID NO: 3 and inhibits expression of a myristolated alanine-rich C kinase substrate (MARCKS) protein having the amino acid sequence of SEQ ID NO: 4 in said cells, wherein the nucleic acid molecule is about 17 nucleotides to about 29 nucleotides in length.

2. The method of claim 1 , wherein the smooth muscle cell response is cell proliferation.

3. The method of claim 1 , wherein the smooth muscle cell response is cell migration.

4. The method of claim 1 , wherein the nucleic acid molecule induces post-transcriptional silencing of at least one gene encoding the MARCKS.

5. The method of claim 1 , wherein the nucleic acid molecule comprises RNA.

6. The method of claim 5 , wherein the RNA is small interfering RNA (siRNA).

7. The method of claim 1 , wherein the vascular smooth muscle cells are present in a vein graft.

8. The method of claim 1 , wherein the vascular smooth muscle cells are human vascular smooth muscle cells.

9. The method of claim 5 , wherein the RNA is double-stranded.

10. A method of inhibiting expression of one or more genes encoding a MARCKS protein having the amino acid sequence of SEQ ID NO: 4 in a vascular smooth muscle cell, the method comprising transfecting said vascular smooth muscle cell with a nucleic acid molecule that comprises a nucleotide sequence that is at least 90% homologous to a portion of SEQ ID NO: 3, wherein said nucleic acid molecule hybridizes to SEQ ID NO: 3 and induces post-transcriptional silencing of said one or more genes, wherein the nucleic acid molecule is about 17 nucleotides to about 29 nucleotides in length.

11. The method of claim 10 , wherein the nucleic acid molecule comprises RNA.

12. The method of claim 11 , wherein the RNA is double-stranded.

13. The method of claim 11 , wherein the RNA is small interfering RNA (siRNA).

14. The method of claim 10 , wherein the vascular smooth muscle cell is present in a vein graft.

15. The method of claim 10 , wherein the vascular smooth muscle cell is a mammalian vascular smooth muscle cell.

16. The method of claim 15 , wherein the vascular smooth muscle cell is a human vascular smooth muscle cell.

17. The method of claim 1 , wherein the nucleic acid molecule comprises a nucleotide sequence that is 100% homologous to a portion of SEQ ID NO:3.

18. The method of claim 10 , wherein the nucleic acid molecule comprises a nucleotide sequence that is 100% homologous to a portion of SEQ ID NO:3.

Assignments (2)
CONFIRMATORY LICENSE Recorded Jan 21, 2011
From: BETH ISRAEL DEACONESS MEDICAL CENTER
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 025675/0763 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 8, 2008
From: MONAHAN, THOMAS S.; LOGERFO, FRANK W.; ANDERSON, NICHOLAS D.
To: BETH ISRAEL DEACONESS MEDICAL CENTER, INC.
Reel/Frame 020490/0888 →
Continuity (3)
Continuation PCTUS2006004823 · Feb 9, 2006
Provisional Application 60651336 · Feb 9, 2005
Related Publication 20080299654A1 · Dec 4, 2008